{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:00:39Z","timestamp":1784718039964,"version":"3.55.0"},"reference-count":89,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA233770"],"award-info":[{"award-number":["R37CA233770"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH2210019"],"award-info":[{"award-number":["W81XWH2210019"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,30]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapy-induced senescence (TIS) is a common outcome of diverse anticancer treatments, including chemotherapy, radiation, and small-molecule inhibitors. Senescence is characterized by stable growth arrest and the senescence-associated secretory phenotype (SASP), which includes various immune mediators. As the role of the immune system in controlling cancer becomes increasingly appreciated, understanding the impact of TIS on the tumor immune microenvironment (TIME) is critically important. Here, we investigated how senescence can be leveraged to enhance antitumor immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the effects of an Aurora kinase A inhibitor (AURKAi), a potent inducer of senescence in melanoma models, using transcriptome and secretome profiling. The role of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway was investigated using imaging, inhibitors, and gene knockout. We also examined the effect of AURKAi on the surface expression of major histocompatibility complex class I (MHC-I) and programmed death-ligand 1 (PD-L1), as well as on signal transducer and activator of transcription 1 (STAT1) activation. In vivo, the effects of AURKAi treatment on the TIME were investigated using spectral cytometry and cell depletion studies. Finally, we assessed combining AURKAi with immune checkpoint blockade (ICB), adoptive cell therapy, and natural killer (NK) cell therapy in murine models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed significant gene expression rewiring and the secretion of immune-related mediators and chemokines associated with AURKAi-induced senescence, which was favorably modulated by a senolytic BCL-2\/xL inhibitor navitoclax. Mechanistically, AURKAi induced the formation of micronuclei linked with the activation of the cGAS-STING pathway, which, in turn, initiated pro-inflammatory transcriptional programs. Senescent melanoma cells exhibited increased surface expression of MHC-I and PD-L1, along with interferon regulatory factor 3 (IRF3) and STAT1 activation, indicating enhanced immunogenicity. In vivo, AURKAi treatment significantly enriched the TIME with activated CD8+ T cells and NK cells, with depletion studies confirming their critical role in antitumor effects. While combining AURKAi with immune checkpoint blockade was not beneficial, AURKAi pretreatment significantly augmented T and NK cell therapies in murine models, resulting in enhanced tumor control and prolonged survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that senescence, specifically when induced by an AURKAi, can be harnessed to promote effector cell engagement in immune-cold tumors, thereby enhancing responsiveness to cell therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013441","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:00:27Z","timestamp":1784714427000},"page":"e013441","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy-induced senescence rewires the melanoma secretome to promote antitumor immune response and augment cell therapies"],"prefix":"10.1136","volume":"14","author":[{"given":"Marina","family":"Capece","sequence":"first","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokiya","family":"Reshetnikova","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nar B","family":"Katuwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"de Lima Bellan","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrendra","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Bharti","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese","family":"Watkins","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Krull","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"},{"name":"Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaopeng","family":"Gu","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"},{"name":"Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ma","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"},{"name":"Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Mittra","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"},{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-913X","authenticated-orcid":false,"given":"Anna E","family":"Vilgelm","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026072203002328000_14.7.e013441.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00821-8"},{"key":"2026072203002328000_14.7.e013441.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081571","article-title":"Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance","volume":"16","author":"Fateeva","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026072203002328000_14.7.e013441.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2026072203002328000_14.7.e013441.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026072203002328000_14.7.e013441.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"2026072203002328000_14.7.e013441.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in Melanoma: Recent Advances and Future Directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026072203002328000_14.7.e013441.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026072203002328000_14.7.e013441.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02961"},{"key":"2026072203002328000_14.7.e013441.9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400087","article-title":"Sequencing of Checkpoint or BRAF\/MEK Inhibitors on Brain Metastases in Melanoma","volume":"3","author":"Ascierto","year":"2024","journal-title":"NEJM Evid"},{"key":"2026072203002328000_14.7.e013441.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26051849","article-title":"Advances in Melanoma and Skin Cancers","volume":"26","author":"Mallardo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026072203002328000_14.7.e013441.11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CMR.0000000000000850","article-title":"Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions","volume":"32","author":"Shui","year":"2022","journal-title":"Melanoma Res"},{"key":"2026072203002328000_14.7.e013441.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"2026072203002328000_14.7.e013441.13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133448","article-title":"Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition","volume":"15","author":"Hassel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026072203002328000_14.7.e013441.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"2026072203002328000_14.7.e013441.15","first-page":"3967","article-title":"Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma","volume":"12","author":"Pillai","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2026072203002328000_14.7.e013441.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612"},{"key":"2026072203002328000_14.7.e013441.17","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061450","article-title":"Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead","volume":"10","author":"Soltantoyeh","year":"2021","journal-title":"Cells"},{"key":"2026072203002328000_14.7.e013441.18","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092379","article-title":"Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer","volume":"10","author":"Sun","year":"2021","journal-title":"Cells"},{"key":"2026072203002328000_14.7.e013441.19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032413","article-title":"Cell Immunotherapy against Melanoma: Clinical Trials Review","volume":"24","author":"Filin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026072203002328000_14.7.e013441.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.03.002"},{"key":"2026072203002328000_14.7.e013441.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"2026072203002328000_14.7.e013441.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01896-9"},{"key":"2026072203002328000_14.7.e013441.23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.hoc.2020.09.005","article-title":"Advanced Melanoma: Resistance Mechanisms to Current Therapies","volume":"35","author":"Haugh","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026072203002328000_14.7.e013441.24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/1061186X.2024.2384071","article-title":"Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals","volume":"32","author":"Wang","year":"2024","journal-title":"J Drug Target"},{"key":"2026072203002328000_14.7.e013441.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.100728","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma","volume":"24","author":"K\u00f6nig","year":"2024","journal-title":"Immunooncol Technol"},{"key":"2026072203002328000_14.7.e013441.26","doi-asserted-by":"crossref","first-page":"1400193","DOI":"10.3389\/fonc.2024.1400193","article-title":"Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"key":"2026072203002328000_14.7.e013441.27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CMR.0000000000000436","article-title":"Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma","volume":"28","author":"Foley","year":"2018","journal-title":"Melanoma Res"},{"key":"2026072203002328000_14.7.e013441.28","doi-asserted-by":"crossref","DOI":"10.3390\/cells13151281","article-title":"Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?","volume":"13","author":"Liu","year":"2024","journal-title":"Cells"},{"key":"2026072203002328000_14.7.e013441.29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab064"},{"key":"2026072203002328000_14.7.e013441.30","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13312"},{"key":"2026072203002328000_14.7.e013441.31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq364"},{"key":"2026072203002328000_14.7.e013441.32","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv406","article-title":"Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment","volume":"108","author":"Vilgelm","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2026072203002328000_14.7.e013441.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02096-7","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","journal-title":"Mol Cancer"},{"key":"2026072203002328000_14.7.e013441.34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-121808-102144"},{"key":"2026072203002328000_14.7.e013441.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-017-0172-3","article-title":"Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence\/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line","volume":"15","author":"Ortiz-Montero","year":"2017","journal-title":"Cell Commun Signal"},{"key":"2026072203002328000_14.7.e013441.36","doi-asserted-by":"publisher","DOI":"10.1101\/gad.17276711"},{"key":"2026072203002328000_14.7.e013441.37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0528"},{"key":"2026072203002328000_14.7.e013441.38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0523"},{"key":"2026072203002328000_14.7.e013441.39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2026072203002328000_14.7.e013441.40","doi-asserted-by":"publisher","DOI":"10.1038\/nature23470"},{"key":"2026072203002328000_14.7.e013441.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01052.x"},{"key":"2026072203002328000_14.7.e013441.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature23449"},{"key":"2026072203002328000_14.7.e013441.43","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-kappaB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026072203002328000_14.7.e013441.44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.623"},{"key":"2026072203002328000_14.7.e013441.45","doi-asserted-by":"crossref","DOI":"10.3390\/v9120376","article-title":"Host Cell Restriction Factors that Limit Influenza A Infection","volume":"9","author":"Villal\u00f3n-Letelier","year":"2017","journal-title":"Viruses"},{"key":"2026072203002328000_14.7.e013441.46","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.115"},{"key":"2026072203002328000_14.7.e013441.47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3"},{"key":"2026072203002328000_14.7.e013441.48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00189"},{"key":"2026072203002328000_14.7.e013441.49","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S75378"},{"key":"2026072203002328000_14.7.e013441.50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/DDDT.S74062","article-title":"Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells","volume":"9","author":"Zhou","year":"2015","journal-title":"DDDT"},{"key":"2026072203002328000_14.7.e013441.51","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s13277-014-2782-3","article-title":"Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo","volume":"36","author":"Qi","year":"2015","journal-title":"Tumor Biol"},{"key":"2026072203002328000_14.7.e013441.52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10366"},{"key":"2026072203002328000_14.7.e013441.53","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.02364-06"},{"key":"2026072203002328000_14.7.e013441.54","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90374-7"},{"key":"2026072203002328000_14.7.e013441.55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608798104"},{"key":"2026072203002328000_14.7.e013441.56","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0089"},{"key":"2026072203002328000_14.7.e013441.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37216-2"},{"key":"2026072203002328000_14.7.e013441.58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2405"},{"key":"2026072203002328000_14.7.e013441.59","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201201378"},{"key":"2026072203002328000_14.7.e013441.60","doi-asserted-by":"crossref","first-page":"111826","DOI":"10.1016\/j.celrep.2022.111826","article-title":"BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis","volume":"41","author":"Bharti","year":"2022","journal-title":"Cell Rep"},{"key":"2026072203002328000_14.7.e013441.61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009299","article-title":"Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses","volume":"4","author":"Vilgelm","year":"2015","journal-title":"Oncoimmunology"},{"key":"2026072203002328000_14.7.e013441.62","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101408","article-title":"Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids","volume":"23","author":"Vilgelm","year":"2020","journal-title":"iScience"},{"key":"2026072203002328000_14.7.e013441.63","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100220","article-title":"Obtaining patient-derived cancer organoid cultures via fine-needle aspiration","volume":"2","author":"Phifer","year":"2021","journal-title":"STAR Protoc"},{"key":"2026072203002328000_14.7.e013441.64","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100212","article-title":"High-throughput drug screening of fine-needle aspiration-derived cancer organoids","volume":"1","author":"Bergdorf","year":"2020","journal-title":"STAR Protoc"},{"key":"2026072203002328000_14.7.e013441.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2018.02.001"},{"key":"2026072203002328000_14.7.e013441.66","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179345","article-title":"A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients","volume":"25","author":"Mallardo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026072203002328000_14.7.e013441.67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00333","article-title":"Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy","volume":"10","author":"Vilgelm","year":"2019","journal-title":"Front Immunol"},{"key":"2026072203002328000_14.7.e013441.68","doi-asserted-by":"crossref","first-page":"1162563","DOI":"10.3389\/fphar.2023.1162563","article-title":"Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma","volume":"14","author":"Hu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026072203002328000_14.7.e013441.69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12967-023-03971-5","article-title":"IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab","volume":"21","author":"Mallardo","year":"2023","journal-title":"J Transl Med"},{"key":"2026072203002328000_14.7.e013441.70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026072203002328000_14.7.e013441.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2026072203002328000_14.7.e013441.72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14712598.2022.2038132","article-title":"Immune checkpoint inhibitors for the treatment of melanoma","volume":"22","author":"Sabbatino","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2026072203002328000_14.7.e013441.73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"2026072203002328000_14.7.e013441.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2026072203002328000_14.7.e013441.75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701479"},{"key":"2026072203002328000_14.7.e013441.76","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat Commun"},{"key":"2026072203002328000_14.7.e013441.77","doi-asserted-by":"crossref","unstructured":"Klinke DJ , Gould A , Pirkey A , et al . A functional comparison of two transplantable syngeneic mouse models of melanoma: B16F0 and YUMM1.7. Biol Open 2025;14. doi:10.1242\/bio.062175","DOI":"10.1242\/bio.062175"},{"key":"2026072203002328000_14.7.e013441.78","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.58347\/tml.2024.1701h","article-title":"Lifileucel (Amtagvi): A Cellular Therapy for Melanoma","volume":"66","year":"2024","journal-title":"Med Lett Drugs Ther"},{"key":"2026072203002328000_14.7.e013441.79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102870","article-title":"Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy","volume":"12","author":"Falcone","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026072203002328000_14.7.e013441.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102209"},{"key":"2026072203002328000_14.7.e013441.81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"2026072203002328000_14.7.e013441.82","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3586"},{"key":"2026072203002328000_14.7.e013441.83","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14266"},{"key":"2026072203002328000_14.7.e013441.84","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177523","article-title":"TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING","volume":"9","author":"Bharti","year":"2024","journal-title":"JCI Insight"},{"key":"2026072203002328000_14.7.e013441.85","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1845332"},{"key":"2026072203002328000_14.7.e013441.86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6208"},{"key":"2026072203002328000_14.7.e013441.87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2018.1417382","article-title":"Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors","volume":"27","author":"Liewer","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"2026072203002328000_14.7.e013441.88","doi-asserted-by":"crossref","unstructured":"Somanchi SS , Senyukov VV , Denman CJ , et al . Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells. JoVE 2011. doi:10.3791\/2540-v","DOI":"10.3791\/2540-v"},{"key":"2026072203002328000_14.7.e013441.89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1895"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:00:35Z","timestamp":1784714435000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":89,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,22]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2025-013441"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013441","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}